A scientist pipetting at a biomedical laboratory on 9 August, 2018. Photo: ALAMY
Opinion
Opinion
Macroscope by Andrew Langer
Indonesia’s policy misstep is Vietnam’s opportunity to seize the sweet spot as Southeast Asia’s pharmaceutical hub
Indonesia is actively driving out biopharmaceutical and other sophisticated ventures, requiring the compulsory licensing of any non-indigenous pharmaceutical products
This intellectual property grab will result in the list of drugs not available in Indonesia to grow even longer
